These data suggest the use of the tumor-targeting ability of IL4RPep-1-EVs as a superior drug delivery approach in IL4R-expressing tumors, including anaplastic thyroid cancer. Here, IL4R is linked to thyroid gland undifferentiated (anaplastic) carcinoma.